Newly Diagnosed Patients With PAH Benefit From Earlier Initiation of Therapy

March 07, 2021 02:30pm

Patients with pulmonary arterial hypertension (PAH) who are treated with selexipag within 6 months of their diagnosis had a reduced risk of morbidity/mortality compared with patients who were treated longer than 6 months after diagnosis.

Podcast: This Week in Managed Care—Updates on Nationwide Vaccine Availability and Other Health News
Cancer Care From the COVID-19 Frontlines: “Flying by the Seat of Our Pants”
Dr Vamshi Rao Discusses Possible Future Guidelines for SMA Care
Does Treatment for CLL Accelerate Myeloid Neoplasms?